

(FILE 'HOME' ENTERED AT 13:21:02 ON 07 SEP 2006)

FILE 'MEDLINE, EMBASE, CAPLUS' ENTERED AT 13:21:18 ON 07 SEP 2006

L1 1073 S (TOLL-LIKE RECEPTOR 7) OR TLR7 OR TLR-7 OR (TOLL-LIKE RECEPTO
L2 68 S L1 AND CD40
L3 47 DUP REM L2 (21 DUPLICATES REMOVED)
L4 5 S L3 AND PY<2003

FILE 'STNGUIDE' ENTERED AT 13:24:47 ON 07 SEP 2006

FILE 'MEDLINE, EMBASE, CAPLUS' ENTERED AT 13:31:54 ON 07 SEP 2006
E KEDL R/AU

L5 92 S E3-E9
L6 28 S L5 AND L1
L7 7 S L6 AND CD40
L8 7 S L7 NOT L4

L4 ANSWER 1 OF 5 MEDLINE on STN
AN 2002718407 MEDLINE
DN PubMed ID: 12480256
TI Natural type I interferon-producing cells as a link between innate and adaptive immunity.
AU Kadowaki Norimitsu; Liu Yong-Jun
CS Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.. kadowaki@kuhp.kyoto-u.ac.jp
SO Human immunology, (2002 Dec) Vol. 63, No. 12, pp. 1126-32. Ref: 42
Journal code: 8010936. ISSN: 0198-8859.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200311
ED Entered STN: 18 Dec 2002
Last Updated on STN: 4 Nov 2003
Entered Medline: 3 Nov 2003

L4 ANSWER 2 OF 5 MEDLINE on STN
AN 2002718405 MEDLINE
DN PubMed ID: 12480254
TI Plasmacytoid dendritic cells: the key to CpG.
AU Rothenfusser Simon; Tuma Evelyn; Endres Stefan; Hartmann Gunther
CS Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany.
SO Human immunology, (2002 Dec) Vol. 63, No. 12, pp. 1111-9. Ref: 87
Journal code: 8010936. ISSN: 0198-8859.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200311
ED Entered STN: 18 Dec 2002
Last Updated on STN: 4 Nov 2003
Entered Medline: 3 Nov 2003

L4 ANSWER 3 OF 5 MEDLINE on STN
AN 2002318849 MEDLINE
DN PubMed ID: 12045249
TI Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets.
AU Ito Tomoki; Amakawa Ryuichi; Kaisho Tsuneyasu; Hemmi Hiroaki; Tajima Kenichirou; Uehira Kazutaka; Ozaki Yoshio; Tomizawa Hideyuki; Akira Shizuo; Fukuhara Shirou
CS First Department of Internal Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi City, Osaka 570-8506, Japan.
SO The Journal of experimental medicine, (2002 Jun 3) Vol. 195, No. 11, pp. 1507-12.
Journal code: 2985109R. ISSN: 0022-1007.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200207
ED Entered STN: 14 Jun 2002
Last Updated on STN: 7 Jul 2002

Entered Medline: 5 Jul 2002

L4 ANSWER 4 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2001375641 EMBASE
TI Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with Cd40 ligand to induce high amounts of IL-12.
AU Krug A.; Towarowski A.; Britsch S.; Rothenfusser S.; Hornung V.; Bals R.; Giese T.; Engelmann H.; Endres S.; Krieg A.M.; Hartmann G.
CS G. Hartmann, Division of Clinical Pharmacology, Medizinische Klinik Innenstadt, Klinikum der LMU, Ziemssenstrasse 1, D-80336 Munich, Germany. ghartmann@lrz.uni-muenchen.de
SO European Journal of Immunology, (2001) Vol. 31, No. 10, pp. 3026-3037. .
Refs: 48
ISSN: 0014-2980 CODEN: EJIMAF
CY Germany
DT Journal; Article
FS 026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 15 Nov 2001
Last Updated on STN: 15 Nov 2001

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:954997 CAPLUS
DN 138:54497
TI Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs
AU Brawand, Pierre; Fitzpatrick, David R.; Greenfield, Brad W.; Brasel, Kenneth; Maliszewski, Charles R.; De Smedt, Thibaut
CS Amgen Inc., Seattle, WA, 98101, USA
SO Journal of Immunology (2002), 169(12), 6711-6719
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English

WEST Search History

[Hide Items](#) | [Restore](#) | [Clear](#) | [Cancel](#)

DATE: Thursday, September 07, 2006

[Hide?](#) [Set Name](#) [Query](#)

[Hit Count](#)

DB=PGPB,USPT,DWPI; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L6	L5 or l1	24
<input type="checkbox"/>	L5	L4 or l3	9
<input type="checkbox"/>	L4	L2 and tlr\$	9
<input type="checkbox"/>	L3	L2 and toll\$	9
<input type="checkbox"/>	L2	noelle-r\$.in. or ahon?n-cor\$.in or kedl-ross\$.in.	46

DB=PGPB,USPT; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L1	((toll-like receptor 7) or (tlr7) or (TLR-7)) same (cd40)	16
--------------------------	----	---	----

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)

L6: Entry 12 of 24

File: PGPB

Oct 6, 2005

DOCUMENT-IDENTIFIER: US 20050221395 A1

TITLE: Methods and products based on oligomerization of stress proteins

Detail Description Paragraph:

[0351] In another embodiment, complexes of the invention are used in combination with one or more biological response modifiers which are agonists or antagonists of various ligands, receptors and signal transduction molecules of the immune system. For examples, the biological response modifiers include but are not limited to agonists of Toll-like receptors (TLR-2, TLR-7, TLR-8 and TLR-9; LPS; agonists of 41BB ligand, OX40 ligand, ICOS, and CD40; and antagonists of Fas ligand, PD1, and CTLA4. These agonists and antagonists can be antibodies, antibody fragments, peptides, peptidomimetic compounds, and polysaccharides.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

L6: Entry 15 of 24

File: PGPB

Mar 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050054590

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050054590 A1

TITLE: Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus

PUBLICATION-DATE: March 10, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Averett, Devron R.	Cardiff By The Sea	CA	US

APPL-NO: 10/931130 [PALM]

DATE FILED: September 1, 2004

RELATED-US-APPL-DATA:

Application is a non-provisional-of-provisional application 60/500339, filed September 5, 2003,

Application is a non-provisional-of-provisional application 60/518996, filed November 10, 2003,

Application is a non-provisional-of-provisional application 60/518997, filed November 10, 2003,

INT-CL-PUBLISHED: [07] A61K 31/7076, A61K 31/522, A61K 31/513, A61K 31/4745

INT-CL-CURRENT:

TYPE	IPC	DATE
CIPS	<u>A61 K 31/519</u>	20060101
CIPS	<u>A61 K 31/7042</u>	20060101
CIPS	<u>A61 K 31/7076</u>	20060101
CIPS	<u>A61 K 31/708</u>	20060101
CIPS	<u>A61 K 31/4738</u>	20060101
CIPS	<u>A61 K 31/4745</u>	20060101
CIPS	<u>A61 K 31/513</u>	20060101
CIPS	<u>A61 K 31/522</u>	20060101

US-CL-PUBLISHED: 514/043; 514/045, 514/269, 514/263.38, 514/292

US-CL-CURRENT: 514/43; 514/263.38, 514/269, 514/292, 514/45

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.

[0001] This application claims the benefit of U.S. Provisional Application No. 60/500,339,

filed Sep. 5, 2003, U.S. Provisional Application No. 60/518,996, filed Nov. 10, 2003, and U.S. Provisional Application No. 60/518,997, filed Nov. 10, 2003.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)